Myocardial strain impairment, heterozygous familial hypercholesterolemia and systemic arterial hypertension: Is there

Antonio Vitarelli1

  • 1Sapienza University, Dept. of Medicine and Cardiology, Via Lima 35, Rome, 00198, Italy.

Insights

Heterozygous familial hypercholesterolemia (heFH) can cause early heart dysfunction, even in asymptomatic individuals. This study found reduced heart strain and increased blood pressure in heFH patients, suggesting preclinical cardiovascular changes.

Area of Science:

  • Cardiology
  • Genetics
  • Metabolic Disorders

Background:

  • Dyslipidemia, particularly heterozygous familial hypercholesterolemia (heFH), is a significant risk factor for premature atherosclerotic cardiovascular disease.
  • Subclinical cardiac dysfunction can be assessed using speckle-tracking echocardiography, evaluating myocardial deformation indices.
  • Previous studies indicated decreased longitudinal and circumferential strain in heFH patients without comorbidities.

Discussion:

  • This study investigated asymptomatic, treatment-naive heFH individuals with normal ejection fraction and no other major risk factors.
  • A slight impairment in global longitudinal strain was observed despite normal standard echocardiographic parameters.
  • Elevated systolic and diastolic blood pressure during exercise treadmill testing in heFH patients may indicate early preclinical hypertension.

Key Insights:

  • Asymptomatic heFH males exhibit reduced left ventricular strain and increased systolic/diastolic blood pressure.
  • High cholesterol levels may contribute to endothelial dysfunction and subsequent cardiovascular damage.
  • These findings highlight potential early cardiovascular changes in heFH patients.

Outlook:

  • Further research should explore the link between myocardial strain impairment and the development of systemic arterial hypertension in hypercholesterolemic individuals.
  • Investigating the long-term cardiovascular outcomes in this patient group is warranted.
  • Understanding these preclinical changes can inform early intervention strategies for heFH.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
109
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
126
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
268
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
284
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
565
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
87